"Emerging Fusion Protein Technologies Drive Innovation in Targeted Therapies Across Autoimmune, Cancer, Metabolic, and Cardiovascular Diseases" Boston, Dec. 11, 2025 (GLOBE NEWSWIRE) -- According to ...
HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, targeting oncology and autoimmune diseases. WuXi Biologics offers end-to-end ...
Theradaptive Initiates Series B to Advance Proprietary Protein-Engineering Technology CARLSBAD, Calif. and FREDERICK, Md., Jan. 12, 2026 /PRNewswire/ -- Alphatec Holdings, Inc. (Nasdaq: ATEC), a ...
HCW Biologics presents HCW9206, a novel fusion protein enhancing CAR-T cell therapy's efficacy and cost-effectiveness against diseases. HCW Biologics Inc. has announced promising results from studies ...
Global contract development and manufacturing organization (CDMO) WuXi Biologics announced a partnership with Taiwan-based ...
The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...
This highlights an important preclinical model that could be successful in humans. The notoriously persistent, difficult-to-treat, lifelong and contagious virus—which insidiously attacks the ...
WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...
Pediatric patients with tenosynovial giant cell tumor: Real-world results from an observational registry. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results